GlassScriptPhysician profile
Eric Tillotson
NPI 1316300080
$530.74
in general payments reported to CMS, 2019-2025
13 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.54 · 2022: $110 · 2023: $82.03 · 2024: $70.93 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $76.54 | 2022-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.95 | 2023-2025 | Jardiance |
| Inspire Medical Systems, INC. | $54.52 | 2024 | Inspire |
| Novo Nordisk INC | $54.50 | 2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $47.54 | 2021-2022 | |
| Abbvie INC. | $41.67 | 2025 | |
| Corium, LLC | $39.53 | 2022 | |
| Shield Therapeutics INC | $38.60 | 2023-2025 | Accrufer |
| Lilly USA, LLC | $33.83 | 2022-2024 | Mounjaro |
| Pfizer INC. | $22.79 | 2021 | |
| Sanofi Pasteur INC. | $20.15 | 2025 | |
| Amgen INC. | $18.94 | 2023 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $14.18 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tillotson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.